

Geertjan van Tienhoven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3600501/publications.pdf>

Version: 2024-02-01

117
papers

11,791
citations

66343

42
h-index

28297

105
g-index

117
all docs

117
docs citations

117
times ranked

11157
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2022, 160, 140-149.	2.8	90
2	Post-operative re-irradiation with hyperthermia in locoregional breast cancer recurrence: Temperature matters. <i>Radiotherapy and Oncology</i> , 2022, 167, 149-157.	0.6	11
3	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1220-1230.	1.6	274
4	A randomized phase-II study of reirradiation and hyperthermia versus reirradiation and hyperthermia plus chemotherapy for locally recurrent breast cancer in previously irradiated area. <i>Acta Oncologica</i> , 2022, 61, 441-448.	1.8	4
5	Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. <i>Modern Pathology</i> , 2021, 34, 4-12.	5.5	32
6	ASO Visual Abstract: Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer – A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 485-487.	1.5	1
7	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 8297-8308.	1.5	19
8	Evaluating differences in respiratory motion estimates during radiotherapy: a single planning 4DMRI versus daily 4DMRI. <i>Radiation Oncology</i> , 2021, 16, 188.	2.7	6
9	The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy. <i>European Journal of Cancer</i> , 2021, 155, 28-37.	2.8	4
10	Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2525-2532.	1.0	21
11	Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 744161.	2.8	5
12	Health care use and remaining needs for support among women with breast cancer in the first 15 months after diagnosis: the role of the GP. <i>Family Practice</i> , 2020, 37, 103-109.	1.9	5
13	Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. <i>European Journal of Cancer</i> , 2020, 125, 69-82.	2.8	36
14	Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020, 125, 83-93.	2.8	98
15	Risk factors of unmet needs among women with breast cancer in the post-treatment phase. <i>Psycho-Oncology</i> , 2020, 29, 539-549.	2.3	20
16	Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. <i>Frontiers in Oncology</i> , 2020, 10, 1112.	2.8	12
17	Reply to S. Shi et al and G.W. Peters et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2945-2946.	1.6	2
18	Internal mammary and medial supraclavicular lymph node chain irradiation in stage III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1602-1610.	10.7	164

#	ARTICLE	IF	CITATIONS
19	Defining short and prolonged breath-holds. <i>British Journal of Radiology</i> , 2020, 93, 20200191.	2.2	3
20	Clinical Feasibility of a High-Resolution Thermal Monitoring Sheet for Superficial Hyperthermia in Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 3644.	3.7	8
21	Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. <i>Biomedicines</i> , 2020, 8, 444.	3.2	9
22	Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. <i>Annals of Surgery</i> , 2020, 271, e102-e104.	4.2	43
23	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1763-1773.	1.6	665
24	Locoregional peritoneal hyperthermia to enhance the effectiveness of chemotherapy in patients with peritoneal carcinomatosis: a simulation study comparing different locoregional heating systems. <i>International Journal of Hyperthermia</i> , 2020, 37, 76-88.	2.5	14
25	High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF1. <i>EMBO Reports</i> , 2020, 21, e48780.	4.5	29
26	Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience. <i>Molecular Oncology</i> , 2020, 14, 2176-2189.	4.6	23
27	Two high-resolution thermal monitoring sheets for clinical superficial hyperthermia. <i>Physics in Medicine and Biology</i> , 2020, 65, 175021.	3.0	8
28	External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	4
29	Occurrence of seeding metastases in resectable perihilar cholangiocarcinoma and the role of low-dose radiotherapy to prevent this. <i>World Journal of Hepatology</i> , 2020, 12, 1089-1097.	2.0	0
30	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. <i>Cancers</i> , 2019, 11, 976.	3.7	63
31	Temperature and thermal dose during radiotherapy and hyperthermia for recurrent breast cancer are related to clinical outcome and thermal toxicity: a systematic review. <i>International Journal of Hyperthermia</i> , 2019, 36, 1023-1038.	2.5	72
32	Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 199-207.	8.1	393
33	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	6.3	223
34	Analysis of clinical data to determine the minimum number of sensors required for adequate skin temperature monitoring of superficial hyperthermia treatments. <i>International Journal of Hyperthermia</i> , 2018, 34, 910-917.	2.5	15
35	Reirradiation + hyperthermia for recurrent breast cancer en cuirasse. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 206-214.	2.0	23
36	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. <i>International Journal of Hyperthermia</i> , 2018, 34, 969-979.	2.5	41

#	ARTICLE	IF	CITATIONS
37	Pain relief after a short course of palliative radiotherapy in pancreatic cancer, the Academic Medical Center (AMC) experience. <i>Acta Oncologica</i> , 2018, 57, 697-700.	1.8	24
38	Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer. <i>The Cochrane Library</i> , 2018, 2018, CD008831.	2.8	54
39	Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1052-1062.	0.8	20
40	Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 504-504.	1.6	11
41	Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA4002-LBA4002.	1.6	120
42	A flexible 70 MHz phase-controlled double waveguide system for hyperthermia treatment of superficial tumours with deep infiltration. <i>International Journal of Hyperthermia</i> , 2017, 33, 1-14.	2.5	7
43	Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 630-638.	2.0	7
44	Thermal Skin Damage During Reirradiation and Hyperthermia Is Time-Temperature Dependent. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 392-399.	0.8	25
45	Addition of MRI for CT-based pancreatic tumor delineation: a feasibility study. <i>Acta Oncologica</i> , 2017, 56, 923-930.	1.8	23
46	Dosimetric effects of anatomical changes during fractionated photon radiation therapy in pancreatic cancer patients. <i>Journal of Applied Clinical Medical Physics</i> , 2017, 18, 142-151.	1.9	14
47	Development of a 70 MHz unit for hyperthermia treatment of deep-seated breast tumors. <i>International Journal of Microwave and Wireless Technologies</i> , 2017, 9, 1317-1324.	1.9	3
48	Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: a multi-institutional study. <i>Radiation Oncology</i> , 2017, 12, 58.	2.7	17
49	Probabilistic treatment planning for pancreatic cancer treatment: prospective incorporation of respiratory motion shows only limited dosimetric benefit. <i>Acta Oncologica</i> , 2017, 56, 398-404.	1.8	5
50	Don't forget the dentist: Dental care use and needs of women with breast cancer. <i>Breast</i> , 2016, 29, 1-7.	2.2	6
51	Non-surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis. <i>The Cochrane Library</i> , 2016, 4, CD003455.	2.8	23
52	Quantitative assessment of biliary stent artifacts on MR images: Potential implications for target delineation in radiotherapy. <i>Medical Physics</i> , 2016, 43, 5603-5615.	3.0	7
53	Oncologists' non-verbal behavior and analog patients' recall of information. <i>Acta Oncologica</i> , 2016, 55, 671-679.	1.8	19
54	Considerable pancreatic tumor motion during breath-holding. <i>Acta Oncologica</i> , 2016, 55, 1360-1368.	1.8	32

#	ARTICLE	IF	CITATIONS
55	Predictors of enduring clinical distress in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 563-572.	2.5	20
56	Abdominal organ motion during inhalation and exhalation breath-holds: pancreatic motion at different lung volumes compared. <i>Radiotherapy and Oncology</i> , 2016, 121, 268-275.	0.6	37
57	Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. <i>Trials</i> , 2016, 17, 127.	1.6	131
58	Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life. <i>Supportive Care in Cancer</i> , 2016, 24, 1617-1623.	2.2	16
59	Rib fractures after reirradiation plus hyperthermia for recurrent breast cancer. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 240-247.	2.0	13
60	Visibility and artifacts of gold fiducial markers used for image guided radiation therapy of pancreatic cancer on MRI. <i>Medical Physics</i> , 2015, 42, 2638-2647.	3.0	44
61	Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2015, 116, 94-99.	0.6	44
62	Radiotherapy or surgery for the axilla in node-positive breast cancer? " Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e54.	10.7	4
63	Dosimetric Advantages of Midventilation Compared With Internal Target Volume for Radiation Therapy of Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 675-682.	0.8	19
64	Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 317-327.	27.0	847
65	All eyes on the patient: the influence of oncologists' nonverbal communication on breast cancer patients' trust. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 161-171.	2.5	53
66	Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: Size matters. <i>Radiotherapy and Oncology</i> , 2015, 117, 223-228.	0.6	60
67	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4569-4575.	7.0	12
68	Differences in respiratory-induced pancreatic tumor motion between 4D treatment planning CT and daily cone beam CT, measured using intratumoral fiducials. <i>Acta Oncologica</i> , 2014, 53, 1257-1264.	1.8	55
69	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3. <i>Psycho-Oncology</i> , 2014, 23, 173-182.	2.3	55
70	Limited Role for Biliary Stent as Surrogate Fiducial Marker in Pancreatic Cancer: Stent and Intratumoral Fiducials Compared. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 641-648.	0.8	26
71	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). <i>European Journal of Cancer</i> , 2014, 50, 2983-2993.	2.8	56
72	Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC Tj ETQq 0 0 rgBT /Overlock 10 Tf 50 67 Td <i>Oncology</i> , The, 2014, 15, 1303-1310.	10.7	1,356

#	ARTICLE	IF	CITATIONS
73	Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: Identification rate and nodal outcome. <i>European Journal of Cancer</i> , 2013, 49, 2093-2100.	2.8	37
74	Interfractional Position Variation of Pancreatic Tumors Quantified Using Intratumoral Fiducial Markers and Daily Cone Beam Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 202-208.	0.8	71
75	Probiotics for the prevention or treatment of chemotherapy or radiotherapy related diarrhoea in cancer patients. <i>The Cochrane Library</i> , 2013, , .	2.8	3
76	Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA1001-LBA1001.	1.6	25
77	Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA1001-LBA1001.	1.6	69
78	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). <i>Lancet</i> , The, 2012, 380, 2018-2027.	13.7	759
79	The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions. <i>European Journal of Cancer</i> , Supplement, 2012, 10, 27-33.	2.2	4
80	Adaptive margin radiotherapy for patients with prostate carcinoma: What's the benefit?. <i>Radiotherapy and Oncology</i> , 2012, 105, 203-206.	0.6	5
81	Reirradiation and hyperthermia for radiation-associated sarcoma. <i>Cancer</i> , 2012, 118, 180-187.	4.1	44
82	Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2011, 98, 261-264.	0.6	16
83	Position Verification for the Prostate: Effect on Rectal Wall Dose. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 462-468.	0.8	7
84	Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 27-33.	3.2	19
85	Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS Trial. <i>Annals of Surgical Oncology</i> , 2010, 17, 1854-1861.	1.5	202
86	Efficacy of radiotherapy for painful bone metastases during the last 12 weeks of life. <i>Cancer</i> , 2010, 116, 2716-2725.	4.1	77
87	Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 731-737.	1.6	163
88	Local and Systemic Outcomes in DCIS Based on Tumor and Patient Characteristics: The Radiation Oncologist's Perspective. <i>Journal of the National Cancer Institute Monographs</i> , 2010, 2010, 178-180.	2.1	10
89	Breast Cancer: Disentangling the Intricate Web. <i>Journal of Clinical Oncology</i> , 2010, 28, e281-e281.	1.6	1
90	Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4450-4456.	1.6	254

#	ARTICLE	IF	CITATIONS
91	Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer: A retrospective study. <i>International Journal of Hyperthermia</i> , 2010, 26, 136-144.	2.5	39
92	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. <i>Lancet Oncology</i> , The, 2010, 11, 1066-1073.	10.7	830
93	Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?. <i>Journal of Clinical Oncology</i> , 2009, 27, 996-997.	1.6	18
94	Duration of Androgen Suppression in the Treatment of Prostate Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 2516-2527.	27.0	865
95	Prognosis of patients with locally recurrent breast cancer. <i>American Journal of Surgery</i> , 2007, 193, 138.	1.8	0
96	Postmastectomy radiotherapy should not be standard of care for women with 1-3 involved nodes. <i>Radiotherapy and Oncology</i> , 2007, 84, 103-104.	0.6	2
97	Adaptive radiotherapy for invasive bladder cancer: A feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 862-868.	0.8	103
98	Quality Assurance in the EORTC Randomized Trial 22922/10925 Investigating the Role of Irradiation of the Internal Mammary and Medial Supraclavicular Lymph Node Chain Works. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 576-582.	2.0	35
99	The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy. <i>Journal of Clinical Oncology</i> , 2005, 23, 2130-2135.	1.6	564
100	Quality assurance in the EORTC phase III randomised "boost vs. no boost" trial for breast conserving therapy: Comparison of the results of two individual case reviews performed early and late during the accrual period. <i>Radiotherapy and Oncology</i> , 2005, 76, 278-284.	0.6	23
101	Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: A randomised phase III study (EORTC 10974/22002, LAMANOMA) "Why did this study fail?". <i>European Journal of Cancer</i> , 2005, 41, 2787-2788.	2.8	12
102	Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. <i>European Journal of Cancer</i> , 2004, 40, 1674-1681.	2.8	43
103	Influence of bladder and rectal volume on spatial variability of a bladder tumor during radical radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 835-841.	0.8	92
104	Concomitant boost radiotherapy for muscle invasive bladder cancer. <i>Radiotherapy and Oncology</i> , 2003, 68, 75-80.	0.6	63
105	Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. <i>Radiotherapy and Oncology</i> , 2003, 68, 233-240.	0.6	69
106	Quality assurance in the EORTC 22921 trial on preoperative radiotherapy with or without chemotherapy for resectable rectal cancer. <i>European Journal of Cancer</i> , 2002, 38, 1849-1856.	2.8	16
107	Pain management of patients with unresectable peripancreatic carcinoma. <i>World Journal of Surgery</i> , 2002, 26, 715-720.	1.6	25
108	Office hours pulsed brachytherapy boost in breast cancer. <i>Radiotherapy and Oncology</i> , 2001, 59, 273-280.	0.6	16

#	ARTICLE	IF	CITATIONS
109	Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials. <i>Journal of Clinical Oncology</i> , 2001, 19, 1688-1697.	1.6	504
110	The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage Iâ€“III breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 1399-1408.	0.8	85
111	Estrogen Receptor Status in Primary Breast Cancer: Iodine 123â€“labeled cis-111 ² -Methoxy-17Î±-iodovinyl Estradiol Scintigraphy. <i>Radiology</i> , 2001, 220, 774-779.	7.3	24
112	Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. <i>Cancer</i> , 2000, 89, 2222-2229.	4.1	108
113	Local recurrence after breast conservation therapy for early stage breast carcinoma. , 1999, 85, 437-446.		143
114	The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. <i>Radiotherapy and Oncology</i> , 1999, 52, 101-109.	0.6	607
115	Erratum to â€œ The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Studyâ€• [Radiother. Oncol. 52 (1999) 101â€“109]. <i>Radiotherapy and Oncology</i> , 1999, 53, 167.	0.6	5
116	Primary radiotherapy of breast cancer: Treatment results in locally advanced breast cancer and in operable patients selected by positive axillary apex biopsy. <i>Radiotherapy and Oncology</i> , 1992, 25, 1-11.	0.6	28
117	Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	1